Zev A. Wainberg, MD, on Future Research Efforts for Patients With Advanced Gastric Cancer

Video

Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Gastrointestinal (GI) Cancer Symposium, Zev A. Wainberg, MD, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the GI Oncology Program at UCLA, highlighted future research efforts in the advanced gastric cancer space. Some of these pieces of research include large, randomized studies that will aim to further explore the role of pembrolizumab (Keytruda) within this patient population.

Transcript:

Obviously, the landscape has changed. We have frontline data with nivolumab [Opdivo], which has established it as the standard in [patients with a] CPS greater than 5 with chemotherapy. We have the [phase 3] KEYNOTE-811 study [NCT03615326], which established pembrolizumab plus chemotherapy plus trastuzumab [Herceptin] upfront in HER2-positive disease. There are 2 large, randomized phase 3 trials which will clarify the role of pembrolizumab a little bit further. There's something called the [phase 3 KEYNOTE-859] study [NCT03675737], which is a large, global study of pembrolizumab upfront with chemotherapy to look at whether there are any subsets in which you get benefit with chemotherapy plus pembrolizumab over chemotherapy alone. That study is still waiting to read out in the next year or so.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Related Content